As consumer genomics firms ramp up marketing for Alzheimer's risk tests, one support group says experts should help people understand the results and potential negative effects.
Genome-wide association and meta-analyses have uncovered a dozen ADHD-related loci, providing insights into its biology and overlap with other conditions.
Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.
The genetic testing community is having a tough time deciphering FDA's intentions based on its authorization of 23andMe’s PGx test and a recent safety alert.
Time reports that some experts have raised concerns about 23andMe's new direct-to-consumer pharmacogenetic tests.
The market authorization came with a number of caveats and special requirements that 23andMe must follow when selling its PGx tests to consumers.
A genetic counselor-to-be warns in an op-ed in the Los Angeles Times that direct-to-consumer genetic tests only give a snapshot of genetic risk.
The companies intend to study de-identified, population-scale phenotypic and genotypic data to gain unique insights that may support the broader HCM ecosystem.
The partnership will allow people to see their genetic risk with other health data that Seqster pulls from electronic health records and wearables.
The phenome-wide association study focused on SNPs near potential drug target sites with ties to one or more phenotypes that might impact target suitability.
A genomic analysis of modern and ancient maize reveals a complicated domestication history, according to Reuters.
In PLOS this week: MYRF variant linked to congenital diaphragmatic hernia, analysis of the "dragon's blood" red resin produced by traditional medicine plants, and more.
CNBC reports that half of academic researchers leave after about five years.
Researchers have used genetic analysis to confirm a new type of salamander, the New York Times reports.